Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
Caoilfhionn M Connolly, Jake A. Ruddy, Brian J. Boyarsky, Robin K. Avery, William A. Werbel, Dorry L. Segev, Jacqueline Garonzik‐Wang, Julie J. Paik
Topics & Concepts
MedicineReactogenicityTolerabilityVaccinationAdverse effectInternal medicinePopulationImmunogenicityCohortImmunologyPediatricsImmune systemEnvironmental healthSARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchImmunotherapy and Immune Responses